AzTrials
AzTrials

Premature BirthEarly Phase 1NCT04004091

Prenatal Administration of Spermine Promotes Maturation of Premature Fetal Gut Epithelial Tight Junction: Experimental Study on Fetal Rabbit

A Early Phase 1 study testing Spermine in people with Premature Birth and NEC, run by dr. Riana Pauline Tamba, SpB(K)BA at 1 site in Indonesia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Infections, particularly on the gastrointestinal tract, has been known to be one of the leading causes of death in preterm infants. This is due to the immaturity of the intestinal epithelial cells. Recent studies have shown that polyamines have a role on the development of cells during embryonal phase. Read more about this study

Who is it for?
Ages 24 to 28 daysHealthy volunteers can take part
Conditions the study is for
Premature Birth, NEC
What is being tested?
Spermine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
1 siteIndonesia
Study dates
1 Mar 2019to 30 Sep 2019
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 24 to 28 days
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Intestinal tissue of fetal rabbit that is prematurely alive

Who cannot join

  • Intestinal tissue of fetal rabbit that is dead before termination
  • Intestinal tissue of fetal rabbit, in which the parent died before termination

Trial locations and contacts

1 site in 1 country.

Indonesia1 site
  • Dr. Cipto Mangunkusumo National Hospital

    Jakarta Pusat, Jakarta Special Capital Region, 10340

Other trials in Indonesia

About this study

Official title: Prenatal Administration of Oral Spermine Promotes Maturation of Premature Fetal Gut Epithelial Tight Junction: Experimental Study on Oryctolagus Cuniculus

Infections, particularly on the gastrointestinal tract, has been known to be one of the leading causes of death in preterm infants. This is due to the immaturity of the intestinal epithelial cells. Recent studies have shown that polyamines have a role on the development of cells during embryonal phase. By this experimental study, the investigators would like to evaluate the administration of spermine on the maturation of premature fetal gut epithelial tight junction.

Read the detailed description

This experimental study is conducted with minimum 24 subjects which divided into 6 groups; 1) 24-days pregnant and is given prenatal spermine, 2) 26-days pregnant and is given prenatal spermine, 3) 28-days pregnant and is given prenatal spermine, 4) 24-days pregnant and is not given prenatal spermine, 5) 26-days pregnant and is not given prenatal spermine, and 6) 28-days pregnant and is not given prenatal spermine. At the end of desired pregnancy period, hysterectomy is done and fetus are born. From each parent subject, three fetal samples are chosen using a random sampling. Intestinal tissues are taken from each fetal sample to be examined. Several data will be collected i.e. occludin, β-catenin, and β-actin, as well as histological morphologies.

Conditions
Premature Birth, NEC
Being tested
Spermine
Keywords
Premature Birth, Spermine, Necrotizing Enterocolitis, Tight Junction
Medical subject headings
Premature Birth, Enterocolitis, Necrotizing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SpermineBiological

    Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.

Study groups in NCT04004091
Study groupRoleWhat they receive
24-Day Spermine GroupExperimentalSubjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
Receives: Biological: Spermine
26-Day Spermine GroupExperimentalSubjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
Receives: Biological: Spermine
28-Day Spermine GroupExperimentalSubjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
Receives: Biological: Spermine
24-Day Non Spermine GroupNo interventionSubjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
26-Day Non Spermine GroupNo interventionSubjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
28-Day Non Spermine GroupNo interventionSubjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occludin

    Measurement of occludin (ng/mg protein) from intestinal tissue sample is assessed using Rabbit Occludin ELISA Kit

    Measured: 2 weeks

  2. β-catenin

    Measurement of β-catenin (pg/mg protein) from intestinal tissue sample is assessed using Rabbit β-Catenin ELISA Kit

    Measured: 2 weeks

  3. β-actin

    Measurement of β-actin (ng/mg protein) from intestinal tissue sample is assessed using β-Actin ELISA Kit

    Measured: 2 weeks

Secondary outcomes (1)
  1. Histologic Findings

    Identifying the development of epithelial tight junction cells based on the morphologic findings of the villi structure, including Goblet cells' distribution, enterocytes, enteroendocrine cells, and crypts.

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2019
  2. Study start1 Mar 2019
  3. Primary completion30 Sep 2019
  4. Study completion30 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04004091
Sponsor's protocol ID
tight junction, spermine
Status last verified
Mar 2020
First submitted
26 Jun 2019
Last updated
17 Mar 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • van Wettere WH, Willson NL, Pain SJ, Forder RE. Effect of oral polyamine supplementation pre-weaning on piglet growth and intestinal characteristics. Animal. 2016 Oct;10(10):1655-9. doi: 10.1017/S1751731116000446. Epub 2016 Mar 21.

    PubMed 26997172
  • Peulen O, Gharbi M, Powroznik B, Dandrifosse G. Differential effect of dietary spermine on alkaline phosphatase activity in jejunum and ileum of unweaned rats. Biochimie. 2004 Jul;86(7):487-93. doi: 10.1016/j.biochi.2004.06.002.

    PubMed 15308338
  • Peulen O, Dandrifosse G. Spermine-induced maturation in wistar rat intestine: a cytokine-dependent mechanism. J Pediatr Gastroenterol Nutr. 2004 May;38(5):524-32. doi: 10.1097/00005176-200405000-00012.

    PubMed 15097442
  • Greco S, Niepceron E, Hugueny I, George P, Louisot P, Biol MC. Dietary spermidine and spermine participate in the maturation of galactosyltransferase activity and glycoprotein galactosylation in rat small intestine. J Nutr. 2001 Jul;131(7):1890-7. doi: 10.1093/jn/131.7.1890.

    PubMed 11435503
  • Peulen O, Pirlet C, Klimek M, Goffinet G, Dandrifosse G. Comparison between the natural postnatal maturation and the spermine-induced maturation of the rat intestine. Arch Physiol Biochem. 1998 Feb;106(1):46-55. doi: 10.1076/apab.106.1.46.4392.

    PubMed 9783060
  • Wery I, Deloyer P, Dandrifosse G. Effects of a single dose of orally-administered spermine on the intestinal development of unweaned rats. Arch Physiol Biochem. 1996;104(2):163-72. doi: 10.1076/apab.104.2.163.12886.

    PubMed 8818200
  • Harada E, Hashimoto Y, Syuto B. Orally administered spermine induces precocious intestinal maturation of macromolecular transport and disaccharidase development in suckling rats. Comp Biochem Physiol A Physiol. 1994 Nov;109(3):667-73. doi: 10.1016/0300-9629(94)90208-9.

    PubMed 8529008

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Spermine in people with Premature Birth and NEC, run by dr. Riana Pauline Tamba, SpB(K)BA at 1 site in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occludin (time frame: 2 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04004091, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in